Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number Sort descending | Lead Group | Study Title | CIRB | Study Status | |
|---|---|---|---|---|---|
| AAML06P1 | COG | A Pilot Study of Lestaurtinib (CEP-701) in Combination with Chemotherapy in Young Patients with Relapsed or Refractory FLT3-mutant Acute Myeloid Leukemia | Pediatric CIRB | Completed | |
| AAML07P1 | COG | A Phase II Pilot Study of Bortezomib (PS-341; Velcade; IND# 58;443) Combined with Reinduction Chemotherapy in Children and Young Adults with Recurrent; Refractory or Secondary Acute Myeloid Leukemia | Pediatric CIRB | Completed | |
| AAML08B1 | COG | Biology Study of Transient Myeloproliferative Disorder (TMD) in Children with Down Syndrome (DS) | Pediatric CIRB | Available to Open | |
| AAML1031 | COG | A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib (IND#114480; NSC# 681239; NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD | Pediatric CIRB | Available to Open | |
| AAML1331 | COG | A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid: A COG Groupwide Phase III Study | Pediatric CIRB | Available to Open | |
| AAML1421 | COG | A Phase 1/2 Study of CPX-351 (NSC# 775341; IND #129443) Alone Followed by Fludarabine; Cytarabine; and G-CSF (FLAG) for Children with Relapsed Acute Myeloid Leukemia (AML) | Pediatric CIRB | Available to Open | |
| AAML1531 | COG | Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome: A COG Groupwide Phase III Study | Pediatric CIRB | Available to Open | |
| AAML1831 | COG | A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations | Pediatric CIRB | Available to Open | |
| AAML18P1 | COG | Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP) | Pediatric CIRB | Available to Open | |
| ABTC-1604 | Alliance | Phase 0/I Study of AMG 232 (KRT 232) Concentrations in Brain Tissue in Patients with Recurrent Glioblastoma and of AMG 232 (KRT 232) in Combination with Radiation in Patients with Newly Diagnosed Glioblastoma and Unmethylated MGMT Promoters | Adult CIRB - Late Phase Emphasis | Available to Open |